174 related articles for article (PubMed ID: 35715633)
1. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
Hollis RL; Croy I; Churchman M; Bartos C; Rye T; Gourley C; Herrington CS
Br J Cancer; 2022 Oct; 127(6):1034-1042. PubMed ID: 35715633
[TBL] [Abstract][Full Text] [Related]
2. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
[TBL] [Abstract][Full Text] [Related]
4. The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy.
Athavale R; Thomakos N; Godfrey K; Kew F; Cross P; de Barros Lopes A; Hatem MH; Naik R
Int J Gynecol Cancer; 2007; 17(5):1025-30. PubMed ID: 17466043
[TBL] [Abstract][Full Text] [Related]
5. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
Rauh-Hain JA; Diver EJ; Clemmer JT; Bradford LS; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Oct; 131(1):46-51. PubMed ID: 23906658
[TBL] [Abstract][Full Text] [Related]
6. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome.
George EM; Herzog TJ; Neugut AI; Lu YS; Burke WM; Lewin SN; Hershman DL; Wright JD
Gynecol Oncol; 2013 Oct; 131(1):42-5. PubMed ID: 23838036
[TBL] [Abstract][Full Text] [Related]
7. Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
Ceppi L; Grassi T; Galli F; Buda A; Aletti G; Lissoni AA; Adorni M; Garbi A; Colombo N; Bonazzi C; Landoni F; Fruscio R
Gynecol Oncol; 2021 Jan; 160(1):64-70. PubMed ID: 33077259
[TBL] [Abstract][Full Text] [Related]
8. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
9. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
10. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
11. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
12. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
13. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
14. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
15. Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract][Full Text] [Related]
16. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
[TBL] [Abstract][Full Text] [Related]
17. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
[TBL] [Abstract][Full Text] [Related]
18. Carcinosarcoma arising from high-grade serous carcinoma of the ovary without estrogen receptor, WT-1, and PAX8 immunoreactivity.
Harada N; Nobuhara I; Haruta N; Higashiura Y; Fujii H; Yamao K; Shimada K
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):110-114. PubMed ID: 35181017
[TBL] [Abstract][Full Text] [Related]
19. Carcinosarcoma of the ovary: a case-control study.
Rauh-Hain JA; Growdon WB; Rodriguez N; Goodman AK; Boruta DM; Schorge JO; Horowitz NS; del Carmen MG
Gynecol Oncol; 2011 Jun; 121(3):477-81. PubMed ID: 21420726
[TBL] [Abstract][Full Text] [Related]
20. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]